Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2017 | 2 |
2018 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy.
Eur J Paediatr Neurol. 2022 Jan;36:78-83. doi: 10.1016/j.ejpn.2021.11.004. Epub 2021 Dec 14.
Eur J Paediatr Neurol. 2022.
PMID: 34929615
Free article.
Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
Schreiber A, Brochard S, Rippert P, Fontaine-Carbonnel S, Payan C, Poirot I, Hamroun D, Vuillerot C; MFM DMD Corticosteroids Group.
Schreiber A, et al. Among authors: fontaine carbonnel s.
Dev Med Child Neurol. 2018 Feb;60(2):185-191. doi: 10.1111/dmcn.13590. Epub 2017 Oct 9.
Dev Med Child Neurol. 2018.
PMID: 28990163
Free article.
Item in Clipboard
Influence of a two-year steroid treatment on body composition as measured by dual X-ray absorptiometry in boys with Duchenne muscular dystrophy.
Vuillerot C, Braillon P, Fontaine-Carbonnel S, Rippert P, André E, Iwaz J, Poirot I, Bérard C.
Vuillerot C, et al. Among authors: fontaine carbonnel s.
Neuromuscul Disord. 2014 Jun;24(6):467-73. doi: 10.1016/j.nmd.2014.03.002. Epub 2014 Mar 12.
Neuromuscul Disord. 2014.
PMID: 24780149
Item in Clipboard
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators.
Bertini E, et al.
Lancet Neurol. 2017 Jul;16(7):513-522. doi: 10.1016/S1474-4422(17)30085-6. Epub 2017 Apr 28.
Lancet Neurol. 2017.
PMID: 28460889
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite